---
title: "LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical… — post author — DecisionGateway"
description: "statement by post author, recorded 2026-11-11 — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03"
meta:
  "og:description": "statement by post author, recorded 2026-11-11 — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical… — post author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statementSaid on 2026-11-11

# **LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.**

A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *其LY03017針對阿爾茨海默病精神病性障礙已在中國進入Ⅱ期臨床並完成首例給藥，LY03020作為全球首個TAAR1/5-HT2CR雙靶點激動劑，同樣將阿爾茨海默病精神病性障礙列為目標適應症。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715548)

## **Discussion**

## **Related claims**

[**The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4a1-70d6-b30d-574523915ce8) [**CM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4d4-7e77-8f21-7ffa591cc937) [**Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c517-7e25-961d-f3132f150ba2) [**Simcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c4ee-71c2-a8c8-2f67c0e9c71f) [**Based on current experimental data, the targets of the three pipelines are relatively clear and have a certain probability of becoming drugs.**昂利康 · statement](https://dgw.tmarket.io/claims/01a1e5e4-63bc-7de4-be99-acf7345f0512) [**After acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.**post author · statement](https://dgw.tmarket.io/claims/01a1e68d-c502-7f47-9c8f-1735fd8c35ae)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03#webpage","@type":"WebPage","description":"statement by post author, recorded 2026-11-11 — verbatim quote and source citation.","name":"LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical… — post author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"LY03017 for psychotic disorders associated with Alzheimer's…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715548","text":"其LY03017針對阿爾茨海默病精神病性障礙已在中國進入Ⅱ期臨床並完成首例給藥，LY03020作為全球首個TAAR1/5-HT2CR雙靶點激動劑，同樣將阿爾茨海默病精神病性障礙列為目標適應症。","url":"/claims/01a1e68d-c4c4-7209-ba78-a0c0c258eb03"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
